Opinion
Published on 26 Oct 2022
Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
in Experimental Therapeutics
- 3,902 views
- 5 citations